Loading...
The role of osteoanabolic agents in the management of patients with osteoporosis
McClung, Michael R. Rothman, Micol S. Lewiecki, E. Michael Hanley, David A. Harris, Steven T. Miller, Paul D. Kendler, David L.
McClung, Michael R.
Rothman, Micol S.
Lewiecki, E. Michael
Hanley, David A.
Harris, Steven T.
Miller, Paul D.
Kendler, David L.
Abstract
Reducing fracture risk is the objective of osteoporosis treatment. Bone-forming osteoporosis drugs increase bone mass, restore bone microarchitecture, and reduce fracture risk more effectively than oral bisphosphonates, providing strong justification for the use of these agents as the initial therapy or after anti-remodeling agents in patients at very high risk of fracture. At the end of a 12-to-24-month course of osteoanabolic therapy, transitioning to a potent anti-remodeling agent maintains and enhances the treatment benefit. This review describes the clinical applications of osteoanabolic therapy for osteoporosis.
Keywords
osteoporosis, osteoanabolic, abaloparatide, romosozumab, teriparatide, sequence
Date
2022
Type
Journal article
Journal
Postgraduate Medicine
Book
Volume
134
Issue
6
Page Range
541-551
Article Number
ACU Department
Mary MacKillop Institute for Health Research
Faculty of Health Sciences
Faculty of Health Sciences
Collections
Relation URI
Source URL
Event URL
Open Access Status
Published as ‘gold’ (paid) open access
License
CC BY-NC-ND 4.0
File Access
Open